- In the News
- Welcome to PDSA
Low-level laser therapy may improve treatment of dangerous bleeding disorder
"A low-intensity type of laser treatment may offer a non-invasive, drug-free treatment for thrombocytopenia – a potentially life-threatening shortage of the blood cells called platelets that are essential to blood clotting. In their paper appearing in Science Translational Medicine, a research team from the Wellman Center for Photomedicine at Massachusetts General Hospital (MGH) reports that low-level laser therapy increased the generation of platelets from precursor cells called megakaryocytes (MKs) and had the same effect in several mouse models of the condition. They also identified the probable mechanism underlying this effect."
- From Mass. General Hospital press release
FDA Request to Cease Blood Collection in Florida
"PPTA is aware of the recent request by the FDA that blood establishments in Dade and Broward counties in the State of Florida cease blood collection. This request has been made as a “prudent measure” because State health officials are investigating a number of Zika infections that are not associated with travel to Zika-affected areas and may represent local transmission of the Zika virus."
- From PPTA Press Release
FDA Issues Final Guidance Documents for Expanded Access Program
"The National Organization for Rare Disorders (NORD) applauds the Food and Drug Administration (FDA) for finalizing its efforts to streamline the process used by patients and their physicians seeking expanded access to investigational new drugs and biologics.
Their release of the final Individual Patient Expanded Access Investigational New Drug Application - Form FDA 3926 - can be used by physicians to request expanded access, often referred to as “compassionate use,” for patients suffering from serious or immediately life-threatening diseases and for whom no comparable or satisfactory alternative therapy is available. The shortened form reduces the time to completion from hours to only 45 minutes; a drastic improvement in alleviating the burden on patients and their physicians.
- From NORD Press Release.
Patients with chronic ITP may have increased infection risk before diagnosis
"Patients with primary chronic immune thrombocytopenia have an increased risk for infections up to 5 years before diagnosis, according to results of an epidemiological study.
Of the 3,121 patients diagnosed with ITP between 2006 and 2012, 1,087 patients were diagnosed with incident chronic ITP (men, n = 531; women, n = 556). The observed annual incidence of chronic ITP was 2.3 per 100,000 people (95% CI, 2.15-2.45)."
- By Healio.com. Ekstrand C, et al. J Thromb Haemost. 2016;doi:10.1111/jth.13267.
First U.S. Zika death reported in Puerto Rico
"A 70-year-old Puerto Rican man died from complications of the Zika virus in February, the Centers for Disease Control and Prevention and the Puerto Rico Department of Health announced Friday (4/29/16). This is the first time in the United States or territories that Zika infection contributed to a death, the CDC said.
The elderly man, who lived in the San Juan metro area, contracted Zika and was treated for symptoms that lasted less than a week, said Tyler Sharp, an epidemiologist at the Centers for Disease Control and Prevention Dengue Branch in San Juan, Puerto Rico.
'"A few days after his recovery, he returned to the hospital with signs of a bleeding disorder and was diagnosed with immune thrombocytopenic purpura, or ITP,' Sharp said."
- By Sandee LaMotte, CNN.
PDSA medical advisor Dr. Michael Tarantino published in The Lancet
The Bleeding & Clotting Disorders Institute (BCDI) is proud to announce that our Medical Director, Dr. Michael Tarantino, is the lead investigator and lead author on an international clinical trial that was published in The Lancet. The abstract describes a study of Nplate® showing reduced rate of bleeding in children affected by immune thrombocytopenic purpura (ITP).
- From BCDI Press Release
"Making the world of ITP a more manageable place to be"
The Platelet Disorder Support Association is dedicated to enhancing the lives of people with immune thrombocytopenia (ITP) and other platelet disorders through:
Education • Advocacy • Research • Support
Comprehensive information on conventional therapies usually prescribed for ITP as well as therapies outside of the usual medical mainstream that some patients with ITP have used successfully.
Advocacy helps build awareness and support for ITP and other platelet disorders. Everyone interested in having more people know about ITP, having greater access to treatment, and getting more funding ITP and related diseases can help.
ITP Conference DVDs, free booklets and pamphlets, diet and lifestyle information, PDSA newsletters, journal articles and abstracts, PDSA E-News.